Impact of side-effects associated with endocrine treatments for advanced breast cancer: Clinicians' and patients' perceptions

Breast

Volumn 5, Issue 4, 1996, Pages 259-264

  Leonard, R C F ^a   Lee, L ^a   Harrison, M E ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Silver Fern Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; HORMONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG TOLERANCE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LETHARGY; LIBIDO; MAJOR CLINICAL STUDY; NAUSEA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOMNOLENCE; SWEATING; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0029816016     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90021-1     Document Type: Article

References (6)

1. Garber J E, Henderson I C. The use of chemotherapy in metastatic breast cancer. Hemato Oncol Clin North Am 1989; 3: 807-821.
2. Henderson I C, Harris J R. Principles in the management of metastatic disease. Breast Diseases, 2nd edn. Philadelphia: JB Lippincott, 1991, p 547.
3. Muss H B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992; 21: 15-26.
4. Muss H B. Chemotherapy of breast cancer in the older patient. Semin Oncol 1995; 22: 14-16.
5. Rose C, Mouridsen H T. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721-728.
6. Coombes R C, Hughes S W M, Dowsett M. 4-Hydroxyandrostenedione: a new treatment for post-menopausal patients with breast cancer. Eur J Cancer Part A Gen Topics 1992; 28A: 1941-1945.